Compare TLX & CLBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TLX | CLBT |
|---|---|---|
| Founded | 2015 | 1999 |
| Country | Australia | Israel |
| Employees | 1184 | 1285 |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.4B |
| IPO Year | N/A | N/A |
| Metric | TLX | CLBT |
|---|---|---|
| Price | $9.69 | $12.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $21.13 | ★ $22.50 |
| AVG Volume (30 Days) | 103.2K | ★ 2.2M |
| Earning Date | 08-19-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $21.45 |
| Revenue Next Year | N/A | $17.47 |
| P/E Ratio | $150.33 | ★ $45.29 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.28 | $11.03 |
| 52 Week High | $18.13 | $19.98 |
| Indicator | TLX | CLBT |
|---|---|---|
| Relative Strength Index (RSI) | 41.51 | 44.64 |
| Support Level | $9.46 | $12.67 |
| Resistance Level | $9.92 | $13.95 |
| Average True Range (ATR) | 0.27 | 0.68 |
| MACD | -0.18 | -0.02 |
| Stochastic Oscillator | 16.04 | 46.71 |
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
Cellebrite DI Ltd provides AI-powered digital investigative and intelligence solutions that help public and private sector customers transform investigative workflows, make digital data more accessible and actionable, and improve the efficiency of mobile research and application security. Its solutions support law enforcement, defense, and intelligence agencies in advancing investigations, border security, counterterrorism, intelligence operations, and cyber operations. The company's software also enables enterprises and service providers to collect and review data for corporate investigations, eDiscovery, incident response, and mobile application validation. It operates in the Americas, APAC, and EMEA, with the majority of revenue from the Americas.